The U.S. Food and Drug Administration approved Abraxane for Injectable Suspension (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) in January 2005 for the treatment of breast cancer after failure of combination chemotherapy for metastatic disease or relapse within six months of adjuvant chemotherapy. Prior therapy should have included an anthracycline unless clinically contraindicated.
A team led by Gang Han, PhD, has designed a human protein-based, tumor-targeting Magnetic Resonance Imaging contrast that can be easily cleared by the body.
Scientists at Johns Hopkins have created a nanoparticle that carries two different antibodies capable of simultaneously switching off cancer cells' defensive properties while switching on a robust anticancer immune response in mice.
A drug first designed to prevent cancer cells from multiplying has a second effect: it switches immune cells that turn down the body's attack on tumors back into the kind that amplify it. This is the finding of a study led by researchers from NYU Langone Medical Center and published recently in Cancer Immunology Research.
Halozyme Therapeutics, Inc., a biotechnology company developing novel oncology and drug-delivery therapies, today announced the first patient has been dosed in its Halo-301 | Pancreatic study, a Phase 3 clinical trial in previously untreated metastatic pancreatic cancer patients.
Oasmia Pharmaceutical AB, a developer of a new generation of drugs within human and veterinary oncology, confirmed the previously published findings from a head-to-head comparison study of its lead human cancer product Paclical and Celgene’s Abraxane, demonstrated superimposable paclitaxel PK profiles. The study was conducted in women with metastatic breast cancer.
Oasmia Pharmaceutical AB, a developer of a new generation of drugs within human and veterinary oncology, confirmed today the previously published findings from a head-to-head comparison study of its lead human cancer product Paclical and Celgene’s Abraxane, demonstrated superimposable paclitaxel PK profiles. The study was conducted in women with metastatic breast cancer.
OncoGenex Pharmaceuticals, Inc. announced today initial results from the Phase 2 Rainier study evaluating apatorsen in combination with ABRAXANE (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) and gemcitabine compared to ABRAXANE and gemcitabine alone in patients with untreated metastatic pancreatic cancer.
Researchers have packaged a widely used cancer drug into nanoparticles, more than doubling its effectiveness at destroying tumors.
Oasmia Pharmaceutical AB, developer of a new generation of drugs within human and veterinary oncology, announced today the topline findings from a head-to-head comparison study of its lead human cancer product candidate Paclical and Celgene's Abraxane, which show similar pharmacokinetic (PK) profiles of the two products. The study was conducted in women with metastatic breast cancer.
Sorrento Therapeutics, Inc. and NantBioScience, Inc., a majority owned subsidiary of NantWorks, LLC, announced today that they have established a joint venture to focus on the development of 'first-in-class' small molecules against targets that have eluded the pharmaceutical industry to date and which may address important drivers of cancer growth including cancer stem cells.
Halozyme Therapeutics, Inc., a biotechnology company developing novel oncology and drug-delivery therapies, today announced interim findings from the ongoing phase 2 clinical study of its investigational new drug PEGPH20 for the potential treatment of patients with metastatic pancreatic cancer.
Halozyme Therapeutics, Inc. and Ventana Medical Systems, Inc., a member of the Roche Group, announced today a global agreement to collaborate on the development of, and for Ventana to ultimately commercialize, a companion diagnostic assay for use with Halozyme's investigational new drug, PEGPH20
US-Australian drug discovery company, Novogen, today announced that studies conducted at The University of Queensland Diamantina Institute revealed that experimental drug, Anisina, killed melanoma cells irrespective of their mutational status.
NantWorks, Inc. and Sorrento Therapeutics, Inc., announced today that they have entered into a binding agreement to initiate a global collaboration to discover and develop novel anti-cancer immunotherapies derived from Sorrento's proprietary G-MAB library against neoepitopes of tumor-specific antigens discovered using NantWorks' proprietary pan-omics based, precision medicine approach.
Halozyme Therapeutics, Inc. today announced that the U.S. Food and Drug Administration has granted Orphan Drug designation for PEGylated recombinant human hyaluronidase (PEGPH20) for the treatment of pancreatic cancer.
NantHealth, a transformational healthcare company converging science and technology through a single integrated clinical platform, will unveil the industry's first, open Clinical Operating System (cOS) for value-based, coordinated care at this year's NHS Confederation Annual Conference and Exhibition.
Sorrento Therapeutics, Inc. ("Sorrento" or the "Company"), a late-stage clinical oncology company developing new treatments for cancer and its associated pain, today announced the pricing of an underwritten public offering of 4,765,000 shares of common stock at a public offering price of $5.25 per share.
Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation, today announced that the European Commission has granted approval for ABRAXANE (paclitaxel formulated as albumin bound nanoparticles, or nab-paclitaxel) in combination with gemcitabine for first-line treatment of adult patients with metastatic adenocarcinoma of the pancreas, or metastatic pancreatic cancer.
As cancer maintains its standing as the second leading cause of death in the U.S., researchers have continued their quest for safer and more effective treatments. Among the most promising advances has been the rise of nanomedicine, the application of tiny materials and devices whose sizes are measured in the billionths of a meter to detect, diagnose and treat disease.
A drug now used to treat a type of lymphoma has shown surprising benefit in preclinical studies of inflammatory breast cancer, according to a researcher at Thomas Jefferson University's Kimmel Cancer Center.